Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JD-RISE: JDB0131 vs delamanid combinations in rifampin-resistant pulmonary tuberculosis
ChiCTR2500108732Phase 2Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of JDB0131 in pulmonary tuberculosis (TB) (3 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Sputum culture conversion rate at 8 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
JDB0131
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2500108732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108732.